Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain
Status:
Terminated
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
A multi-center study to evaluate the efficacy of CHADD (Controlled Heat-Assisted Drug
Delivery) applied over a 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch for the
treatment of breakthrough pain in adult patients with moderate to severe non-malignant
chronic pain. The open-label study arm will last up to 12 days. The double-blind arm will
last up to 15 days. Eligible patients who complete the open-label arm will be allowed to
enroll in the double-blind study arm.